PFE Stock Analysis: Pfizer Inc
Pfizer Inc. is a global biopharmaceutical leader engaged in the research, development, production, marketing, and distribution of a wide array of medicinal and vaccine products worldwide. Its comprehensive portfolio addresses diverse therapeutic areas, including cardiovascular health and women's health, featuring key brands such as the Premarin family and Eliquis. The company also offers advanced biologics, small molecule drugs, immunotherapies, and biosimilars for various conditions, exemplified by Ibrance, Xtandi
- Latest close
- $27.8
- 20-day change
- -3.51%
- Trend state
- NEUTRAL
- Classification
- Healthcare · Drug Manufacturers - General
Market context
Pfizer Inc moved -3.51% over the latest 20-session window. BullRecon currently classifies the broader setup as NEUTRAL.
Latest report
The latest cached company filing period (FY2025 · $62.6B revenue · $7.8B net income) is used alongside annual and quarterly history. Values remain tied to their reported period.
Six-dimension read
Quality is currently the strongest dimension at 5.1/6, while Future is the lowest at 2.6/6. Scores are comparative research signals, not forecasts.